Weiss Multi Strategy Advisers LLC Aveo Pharmaceuticals, Inc. Transaction History

Weiss Multi Strategy Advisers LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $19,010 - $25,078	-2,876 Reduced 4.71%	58,124 $478,000
Q2 2022 Aug 15, 2022	SELL	$3.51 - $6.67 $15,752 - $29,934	-4,488 Reduced 6.85%	61,000 $400,000
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $3,641 - $6,947	-1,156 Reduced 1.73%	65,488 $366,000
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $68,680 - $108,365	14,644 Added 28.16%	66,644 $313,000
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $138,496 - $186,374	27,050 Added 108.42%	52,000 $321,000
Q2 2021 Aug 16, 2021	BUY	$6.21 - $7.45 $5,551 - $6,660	894 Added 3.72%	24,950 $164,000
Q1 2021 May 14, 2021	BUY	$5.97 - $15.28 $143,614 - $367,575	24,056 New	24,056 $176,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.